Mitochondrial dysfunction triggers the pathogenesis of Parkinson's disease in neuronal C/EBPβ transgenic mice

Area of Science:

• Neuroscience
• Mitochondrial Biology
• Parkinson's Disease Pathogenesis

Background:

• Complex I deficiency is linked to Parkinson's disease (PD) via mitochondrial dysfunction and reactive oxidative species (ROS).
• The role of other mitochondrial respiratory chain complexes in PD pathogenesis remains largely unexplored.

Purpose of the Study:

• To investigate if impairment of mitochondrial Complex II or III can induce PD pathologies.
• To identify specific inhibitors and pathways involved in ETC-induced PD.

Main Methods:

• Utilized a cell-based screening to identify Complex II (TTFA) and Complex III (Atovaquone) inhibitors.
• Administered inhibitors to neuronal Thy1-C/EBPβ transgenic mice to assess motor function and PD pathology.
• Investigated the role of Complex II (SDHD gene deletion) in the Substantia Nigra of these mice.

Main Results:

• Inhibition of Complex II or III robustly blocked oxidative phosphorylation, increased ROS, and activated the C/EBPβ/AEP pathway.
• Mice treated with inhibitors exhibited constipation, motor defects, and Lewy body-like inclusions.
• SDHD gene deletion in the Substantia Nigra also triggered ROS and PD pathologies, leading to motor disorders.

Conclusions:

• Mitochondrial electron transport chain (ETC) inactivation is sufficient to trigger PD pathogenesis.
• The C/EBPβ/AEP pathway is a key mediator of dopaminergic neuronal cell death in ETC-induced PD.
• Targeting mitochondrial dysfunction offers a potential therapeutic strategy for PD.